Clinical Trial: Modulatory Effects of Resveratrol Supplement Along With and Without Low Glycemic Index Diet Among Obese Patients With Diabetic Nephropathy

U.S., Oct. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07891975) titled 'Modulatory Effects of Resveratrol Supplement Along With and Without Low Glycemic Index Diet Among Obese Patients With Diabetic Nephropathy' on June 28.

Brief Summary: This 12-week randomized controlled trial evaluated the effects of resveratrol supplementation with and without a low glycemic index (LGI) diet in obese patients with diabetic nephropathy. Resveratrol, particularly at the higher dose combined with an LGI diet, significantly improved anthropometric, hepatic, renal, and biochemical parameters, including BMI, liver enzymes, BUN, UPCR, serum uric acid, phosphorus, and albumin levels. These findings suggest that resveratrol ...